Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoxygenase modulation to reverse carcinogenesis.

I Shureiqi1, S M Lippman

  • 1Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Cancer Research
|August 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunological and classical subtypes of oral premalignant lesions.

Oncoimmunology·2018
Same author

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Leukemia & lymphoma·2016
Same author

The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas.

European journal of gynaecological oncology·2016
Same author

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.

Investigational new drugs·2015
Same author

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Prostate cancer and prostatic diseases·2015
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
Same journal

MIF-CD74 Signaling Defines a Brain-Specific Immune Vulnerability in Metastasis and Neurologic Disease.

Cancer research·2026
Same journal

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Cancer research·2026
See all related articles

New research identifies lipoxygenases (LOXs) as key targets for cancer chemoprevention. Modulating LOX activity could shift polyunsaturated fatty acid metabolism, offering a novel approach to prevent cancer development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Polyunsaturated fatty acid metabolism is linked to carcinogenesis.
  • Lipoxygenases (LOXs) play critical roles in this process, with some promoting and others inhibiting cancer.
  • 15-LOX-1 is notably down-regulated in colorectal cancer.

Purpose of the Study:

  • To explore novel molecular targets for cancer chemoprevention based on LOX pathways.
  • To investigate the role of LOX balance in carcinogenesis.
  • To propose LOX modulators as a new chemoprevention strategy.

Main Methods:

  • Review of recent studies on LOX metabolism and cancer.
  • Analysis of the relationship between nonsteroidal anti-inflammatory drugs, 15-LOX-1, and cancer cell apoptosis.

Related Experiment Videos

  • Examination of LOX activity in colorectal, esophageal, and prostatic carcinogenesis models.

    • Main Results:

    • 15-LOX-1 and its product 13-S-hydroxyoctadecadienoic acid show anticarcinogenic activity.
    • Nonsteroidal anti-inflammatory drugs' efficacy is linked to 15-LOX-1 induction.
    • Carcinogenesis involves a shift in LOX balance towards procarcinogenic pathways (5-, 8-, 12-LOX, COX-2).

    Conclusions:

    • A dynamic balance of LOX pathways shifts during carcinogenesis.
    • Targeting LOX modulators can restore the balance towards anticarcinogenic metabolism.
    • This approach offers a novel strategy for cancer chemoprevention.